Antheia’s 2024 in Review: A Year Of Collaboration
As we reflect on 2024, it’s been a significant year of collaboration, with every Antheia employee and partner helping us move closer toward our mission of transforming pharmaceutical supply chains and ending essential medicine shortages. No one person, company, or organization can solve a daunting global problem like drug shortages alone, but we have made […]
Synthetic Biology at Scale: Less Disruption, More Cohesion
For synthetic biology companies, scaling up means reaching out—working with government bodies, identifying partners, and securing manufacturing capacity
Antheia at SynBioBeta 2024: Scaling Highly Engineered Strains
Antheia was a proud sponsor of this year’s SynBioBeta, the Global Synthetic Biology Conference hosted annually in the San Francisco Bay Area.
U.S. Secretary of State Antony J. Blinken Visits Antheia to Discuss Biotechnology Innovation
In early May, U.S. Secretary of State Antony J. Blinken visited Antheia, HQ in Menlo Park, California for a tour of our labs and a panel discussion with innovators in the biotechnology industry
Antheia’s 2023 in Review: A Year Of Transformation
Dear colleagues, friends, and supporters: As we approach 2024, we want to take a moment to look back over an absolutely astounding year of progress for our business and give thanks to the many who made it possible. Nearly a decade of hard work culminated in an industry-first achievement here at Antheia. In August, we […]
Antheia’s 2022 in Review: A Year of Value
This year has been ripe with growth, major achievements, and opportunities to showcase who and what make Antheia the visionary business it is. Nearly eight years ago, we co-founded Antheia…
Demystifying Synthetic Biology Part V: The Product is Key in Downstream Processing
Upstream bioprocessing – better known in biomanufacturing as fermentation – is directly followed by downstream bioprocessing (DSP). Just as fermentation is all about maximizing the production of a target compound, DSP focuses
Syn Bio Companies Put the Earth into Focus
While some synthetic biology companies are using biology to improve our food, clothes, and medicine, others are turning their attention to helping the Earth.
On Heels of $17 Billion SPAC Deal, Ginkgo Inks Collab with Synthetic Biology Firm
California synthetic biology firm Antheia has joined forces with Boston-based biotech company Ginkgo Bioworks to strengthen its efforts to develop and produce essential medicines to treat a wide range of diseases…
Antheia and Ginkgo Bioworks Announce Partnership to Accelerate Production of Essential Medicines using Synthetic Biology
Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, and Ginkgo Bioworks, which is building the leading horizontal platform for cell programming, today announced a partnership to accelerate the development…